A three-dimensional (3D) bioprinting technology capable of eliminating cancer cells using the function of immune cells has been developed for the first time in the world.
Xyphos, Kelonia partner for immuno-oncology drug development
Share this article Xyphos will oversee the development and marketing of the products resulting from this joint research. Credit: fotohunter / Shutterstock.com. Astellas subsidiary Xyphos